Emmanuel Balogun

Dr. Emmanuel Balogun

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TSTomoo Shiba
Tomoo Shiba
YKYasutoshi Kido
Yasutoshi Kido
KSKimitoshi Sakamoto
Kimitoshi Sakamoto
DIDaniel Inaoka
Daniel Inaoka
CTChiaki Tsuge
Chiaki Tsuge
KKKiyoshi Kita
Kiyoshi Kita
In addition to haem copper oxidases, all higher plants, some algae, yeasts, molds, metazoans, and pathogenic microorganisms such as Trypanosoma brucei contain an additional terminal oxidase, the cyanide-insensitive alternative oxidase (AOX). AOX is a diiron carboxylate protein that catalyzes the four-electron reduction of dioxygen to water by ubiquinol. In T. brucei, a parasite that causes human African sleeping sickness, AOX plays a critical role in the survival of the parasite in its bloodstream form. Because AOX is absent from mammals, this protein represents a unique and promising therapeutic target. Despite its bioenergetic and medical importance, however, structural features of any AOX are yet to be elucidated. Here we report crystal structures of the trypanosomal alternative oxidase in the absence and presence of ascofuranone derivatives. All structures reveal that the oxidase is a homodimer with the nonhaem diiron carboxylate active site buried within a four-helix bundle. Unusually, the active site is ligated solely by four glutamate residues in its oxidized inhibitor-free state; however, inhibitor binding induces the ligation of a histidine residue. A highly conserved Tyr220 is within 4 Å of the active site and is critical for catalytic activity. All structures also reveal that there are two hydrophobic cavities per monomer. Both inhibitors bind to one cavity within 4 Å and 5 Å of the active site and Tyr220, respectively. A second cavity interacts with the inhibitor-binding cavity at the diiron center. We suggest that both cavities bind ubiquinol and along with Tyr220 are required for the catalytic cycle for O 2 reduction.

Verified
Journal Article
Open access
PDF file
DIDaniel Inaoka
Daniel Inaoka
TSTomoo Shiba
Tomoo Shiba
DSDan Sato
Dan Sato
EBEmmanuel Balogun
Emmanuel Balogun
TSTsuyoshi Sasaki
Tsuyoshi Sasaki
SHShigeharu Harada
Shigeharu Harada
Recent studies on the respiratory chain of Ascaris suum showed that the mitochondrial NADH-fumarate reductase system composed of complex I, rhodoquinone and complex II plays an important role in the anaerobic energy metabolism of adult A. suum. The system is the major pathway of energy metabolism for adaptation to a hypoxic environment not only in parasitic organisms, but also in some types of human cancer cells. Thus, enzymes of the pathway are potential targets for chemotherapy. We found that flutolanil is an excellent inhibitor for A. suum complex II (IC50 = 0.058 μM) but less effectively inhibits homologous porcine complex II (IC50 = 45.9 μM). In order to account for the specificity of flutolanil to A. suum complex II from the standpoint of structural biology, we determined the crystal structures of A. suum and porcine complex IIs binding flutolanil and its derivative compounds. The structures clearly demonstrated key interactions responsible for its high specificity to A. suum complex II and enabled us to find analogue compounds, which surpass flutolanil in both potency and specificity to A. suum complex II. Structures of complex IIs binding these compounds will be helpful to accelerate structure-based drug design targeted for complex IIs.

23 December 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
MUMarzuq A. Ungogo
Marzuq A. Ungogo
GEGodwin Unekwuojo Ebiloma
Godwin Unekwuojo Ebiloma
NINahandoo Ichoron
Nahandoo Ichoron
JIJohn O. Igoli
John O. Igoli
HKHarry De Koning
Harry De Koning
EBEmmanuel Balogun
Emmanuel Balogun
The West African country Nigeria features highly diverse vegetation and climatic conditions that range from rain forest bordering the Atlantic Ocean in the South to the Desert (Sahara) at the Northern extreme. Based on data from the World Conservation Monitoring Center of the United Nations Environmental Protection, Nigeria, with ~5,000 documented vascular plants, ranks amongst the top 50 countries in terms of biodiversity. Such a rich biodiversity implies that the country is rich in diverse secondary metabolites—natural products/unique chemicals produced by the plant kingdom to confer selective advantages to them. Like many tropical countries, Nigeria is also endemic to numerous infectious diseases particularly those caused by parasitic pathogens. These phytochemicals have been exploited for the treatment of diseases and as a result, a new branch of chemistry, natural product chemistry, has evolved, to try to reproduce and improve the therapeutic qualities of particular phytochemicals. In this review, we have compiled a compendium of natural products, isolated from Nigerian flora, that have been reported to be effective against certain protozoan parasites with the aim that it will stimulate interests for further investigations, and give impetus to the development of the natural products into registered drugs. In total 93 structurally characterized natural compounds have been identified with various levels of anti-parasite activity mainly from Nigerian plants. The synthesis protocol and molecular target for some of these natural anti-parasite agents have been established. For instance, the anti-plasmodial compound fagaronine (7), a benzophenanthridine alkaloid from Fagara zanthoxyloides has been successfully synthesized in the laboratory, and the anti-trypanosomal compound azaanthraquinone (55) elicits its effect by inhibiting mitochondrial electron transfer in trypanosomes. This review also discusses the barriers to developing approved drugs from phytochemicals, and the steps that should be taken in order to accelerate the development of new antiparasitics from the highlighted compounds.

1 March 2018 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
EHEndah Dwi Hartuti
Endah Dwi Hartuti
DIDaniel Inaoka
Daniel Inaoka
KKKeisuke Komatsuya
Keisuke Komatsuya
YMYukiko Miyazaki
Yukiko Miyazaki
RMRussell J. Miller
Russell J. Miller
KKKiyoshi Kita
Kiyoshi Kita

29 January 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
GEGodwin Unekwuojo Ebiloma
Godwin Unekwuojo Ebiloma
EBEmmanuel Balogun
Emmanuel Balogun
EDEduardo cueto diaz
Eduardo cueto diaz
HKHarry De Koning
Harry De Koning
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville

28 January 2023 in Current Tropical Medicine Reports
Verified
Journal Article
Closed access
PDF file
OAOluwafemi A. Adepoju
Oluwafemi A. Adepoju
OAOlubunmi A. Afinowi
Olubunmi A. Afinowi
ATAbdullah M. Tauheed
Abdullah M. Tauheed
ADAmmar U. Danazumi
Ammar U. Danazumi
LDLamin B. S. Dibba
Lamin B. S. Dibba
EBEmmanuel Balogun
Emmanuel Balogun